Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Contineum TherapeuticsCTNM +3.07%17 Debt-to-EBITDA is -0.10 as of Jun. 2026. GuruFocus rates CTNM with a GF Score™ of 17/100. The stock has 3 warning signs investors should review. Among 296 Biotechnology companies, Contineum Therapeutics ranks worse than 337837.5% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Contineum Therapeutics's Debt-to-EBITDA or its related term are showing as below:
CTNM'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.25 Med: -0.12 Max: 0.02
Current: -0.1
During the past 5 years, the highest Debt-to-EBITDA Ratio of Contineum Therapeutics was 0.02. The lowest was -0.25. And the median was -0.12.
CTNM's Debt-to-EBITDA is ranked worse than 100% of 296
companies
in the Biotechnology industry
Industry Median: 1.185
vs CTNM: -0.10
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Contineum Therapeutics Debt-to-EBITDA Related Terms
Contineum Therapeutics Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Contineum Therapeutics's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CTNM vs FDMT, PRME, ARVN: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, Contineum Therapeutics's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Contineum Therapeutics Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Contineum Therapeutics's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Contineum Therapeutics's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Contineum Therapeutics (CTNM) has a Debt-to-EBITDA of -0.10 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Contineum Therapeutics. According to the industry distribution chart, Contineum Therapeutics ranks #999999 out of 296 companies in the Biotechnology industry.
Is Contineum Therapeutics' Debt-to-EBITDA too high?
Contineum Therapeutics' current Debt-to-EBITDA is -0.10. Based on the distribution chart, Contineum Therapeutics ranks #999999 out of 296 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Contineum Therapeutics has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Contineum Therapeutics' Debt-to-EBITDA compare to FDMT and PRME?
According to the Biotechnology industry distribution chart, Contineum Therapeutics ranks #999999 out of 296 companies for Debt-to-EBITDA. This places Contineum Therapeutics in the lower half of its industry. The industry median Debt-to-EBITDA is 1.19. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.19, based on 296 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Contineum Therapeutics. For the Biotechnology industry, the median Debt-to-EBITDA is 1.19 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Contineum Therapeutics's current Debt-to-EBITDA is -0.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Contineum Therapeutics stock overvalued right now?
Contineum Therapeutics (CTNM) has a current Debt-to-EBITDA of -0.10. The current Debt-to-EBITDA is -0.10. Contineum Therapeutics' overall GF Score™ is 17/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Contineum Therapeutics (CTNM), the current Debt-to-EBITDA is -0.10 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.
17GF Score
Get the complete analysis for CTNM
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CTNM has been successfully added to your 
